STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLPT
  4. [Form 4] ClearPoint Neuro, Inc. Insider Trading Activity

ClearPoint Neuro (CLPT) CEO gets 26,568 RSU shares, withholds 9,533 for taxes

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. director and CEO Joseph Burnett settled restricted stock units into common shares on March 3, 2026. He acquired 26,568 shares of common stock upon vesting of restricted stock units, each representing one share of common stock.

To cover tax withholding obligations tied to this vesting, 9,533 common shares were delivered to ClearPoint Neuro at $8.84 per share. Following these transactions, Burnett held 29,534 shares of common stock directly and 193,231 shares indirectly through the Joseph M. Burnett Trust dated 10/20/2022.

Positive

  • None.

Negative

  • None.
Insider BURNETT JOSEPH
Role CEO and President
Type Security Shares Price Value
Exercise Restricted Stock Units 26,568 $0.00 --
Exercise Common Stock 26,568 $0.00 --
Tax Withholding Common Stock 9,533 $8.84 $84K
holding Common Stock -- -- --
Holdings After Transaction: Restricted Stock Units — 106,273 shares (Direct); Common Stock — 39,067 shares (Direct); Common Stock — 193,231 shares (Indirect, See Footnote)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
BURNETT JOSEPH
(Last) (First) (Middle)
C/O CLEARPOINT NEURO, INC.
120 S. SIERRA AVE., SUITE 100
(Street)
SOLANA BEACH CA 92075
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
CEO and President
3. Date of Earliest Transaction (Month/Day/Year)
03/03/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 03/03/2026 M 26,568 A (1) 39,067 D
Common Stock 03/03/2026 F 9,533(2) D $8.84 29,534 D
Common Stock 193,231 I See Footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Units (1) 03/03/2026 M 26,568 (1) (1) Common Stock 26,568 (1) 106,273 D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of ClearPoint Neuro, Inc. ("CLPT") common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date.
2. Represents the amount of shares delivered to CLPT to satisfy applicable tax withholding obligations in connection with the vesting of shares of restricted stock.
3. These shares are owned directly by the Joseph M. Burnett Trust dated 10/20/2022 and indirectly by Joseph M. Burnett as trustee of the trust.
/s/ Danilo D'Alessandro, by Power of Attorney for Joseph M. Burnett 03/05/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What did ClearPoint Neuro (CLPT) CEO Joseph Burnett report in this Form 4?

Joseph Burnett reported settlement of 26,568 restricted stock units into common shares on March 3, 2026. The filing also shows shares delivered to ClearPoint Neuro to satisfy tax withholding obligations and updates his direct and indirect share ownership totals.

How many ClearPoint Neuro (CLPT) shares vested for Joseph Burnett in this filing?

The filing shows 26,568 restricted stock units converted into an equal number of ClearPoint Neuro common shares on their scheduled vesting date. Each restricted stock unit represented a contingent right to receive one share of CLPT common stock upon vesting.

How many ClearPoint Neuro (CLPT) shares were used to cover Joseph Burnett’s taxes?

The Form 4 reports that 9,533 common shares were delivered to ClearPoint Neuro to satisfy applicable tax withholding obligations, at a price of $8.84 per share. This transaction is coded as a tax-withholding disposition.

What is Joseph Burnett’s direct ClearPoint Neuro (CLPT) share ownership after these transactions?

After the reported transactions, Joseph Burnett directly owned 29,534 shares of ClearPoint Neuro common stock. This total reflects both the vesting of 26,568 shares and the delivery of 9,533 shares to the company for tax withholding.

How many ClearPoint Neuro (CLPT) shares does Joseph Burnett hold indirectly through a trust?

The filing states that 193,231 shares of ClearPoint Neuro common stock are owned by the Joseph M. Burnett Trust dated 10/20/2022. These shares are reported as being indirectly owned by Joseph Burnett in his capacity as trustee of the trust.

Does this ClearPoint Neuro (CLPT) Form 4 show an open-market stock sale by Joseph Burnett?

The filing does not show an open-market sale. It records restricted stock unit vesting and a tax-withholding disposition, where 9,533 shares were delivered to ClearPoint Neuro to cover tax obligations rather than being sold on the open market.